Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population

Abstract

Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Progression-free survival at 24 months (PFS24) constitutes a survival predictor for some lymphomas but has not been examined in Asian populations. We retrospectively investigated whether PFS24 was predictive of survival outcomes after CHOP treatment in 73 Japanese patients with PTCL. Patients without PFS24 had shorter median subsequent overall survival (OS) (20.2 vs. 121.0 months, p < 0.001) and shorter median subsequent progression-free survival (5.0 vs. 17.1 months, p = 0.03). Patients without PFS24 had worse overall (62.5% vs. 100%) and complete response rates (45.8% vs. 96.0%) (both p < 0.001). PFS24 absence (hazard ratio: 3.34, p = 0.004) and poor performance status (hazard ratio: 3.17, p = 0.04) were independently predictive of shorter OS. These findings suggest that PFS24 is predictive of survival after CHOP treatment in Japanese patients with PTCL.

Keywords:

• Lymphoma and Hodgkin disease
• non-Hodgkin lymphoma
• T-cell lymphoma
• PTCL
• PFS24
• prognostication

Acknowledgments

We thank all staff members and patients involved in this study. We also thank Ryan Chastain-Gross, Ph.D., from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.

Disclosure statement

NN, YM, and MY have insourced commissioned jobs from by Chugai Pharmaceuticals Co., Ltd. NN has received honoraria from Celgene.YT has received honoraria from Bristol-Myers Squibb, Celgene, Janssen, Novartis Pharma, and Takeda Pharmaceutical Co., Ltd. The remaining authors declare no competing financial interests regarding this study.

Author contributions

YS designed the study, reviewed the literature, performed data analysis, and wrote the initial draft of the manuscript. MY, TF, YT, and NT provided study materials and revised the manuscript. HU, NI, YM, and NN provided study materials. NT and KT reviewed the pathological materials and performed lymphoma diagnosis. All authors read and approved the final draft of the manuscript.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.